U.S. health agencies said on Thursday they are seeking to develop a universal vaccine technology to target multiple strains ...

Moderna Inc. shares declined after the company’s first-quarter vaccine sales missed estimates and it disclosed a delay in the ...

Kennedy and FDA Commissioner Marty Makary’s approach to assessing vaccines could put Covid boosters out of reach.

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

From STAT’s Jason Mast: Moderna said this morning in its earnings report it planned to cut costs by around $1.5 billion by ...

“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...

Several current and former FDA employees who spoke to Inside Medicine on the condition of anonymity have come to see the ...

Public health experts worry the policy change would not only cast doubt on the safety and effectiveness of vaccines but would limit production and access. Separately, a decades-long pursuit of ...

According to the WSJ, the universal vaccine project is being pioneered by two recently appointed senior scientists in the NIH ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...